Eclipta (Eclipta prostrata)

Eclipta prostrata is an Ayurvedic herb whose primary bioactive compounds — wedelolactone and ecliptasaponins — drive its pharmacological activity. Wedelolactone inhibits NF-κB signaling and activates mTOR pathways, underpinning its anti-inflammatory and hair-growth-promoting properties.

Origin & History

Eclipta prostrata, also known as false daisy, is an annual herb from the Asteraceae family, native to tropical and subtropical regions of Asia, including India, Nepal, and Bangladesh. The entire plant is used medicinally, with extracts typically made using methanol or ethanol and analyzed through LC/MS for bioactive profiling.

Historical & Cultural Context

Eclipta prostrata has been used for centuries in traditional medicine systems in India, Nepal, and Bangladesh as a tonic for various ailments, including skin diseases, liver disorders, and hair loss. Its ethnomedicinal applications are supported by pharmacological evidence for several health benefits.

Health Benefits

• Promotes hair growth by inducing anagen phase and activating mTOR signaling in mice (preclinical study).
• Exhibits antiproliferative effects on cancer cells like AGS, A549, HT-29, without affecting normal cells (in vitro study, PMID: 37959773).
• Demonstrates anti-inflammatory effects by regulating cytokine pathways in cell studies.
• Supports liver health with traditional hepatoprotective claims (traditional use alignment).
• Acts as an antioxidant, as evidenced by the presence of flavonoids and polyphenols (compound analysis).

How It Works

Wedelolactone, a coumestan compound in Eclipta prostrata, inhibits IKK (IκB kinase), thereby suppressing NF-κB nuclear translocation and downstream pro-inflammatory cytokine production including TNF-α and IL-6. In hair follicle models, Eclipta extract activates mTOR signaling and promotes transition from the telogen to anagen phase, potentially via Wnt/β-catenin pathway stimulation. Ecliptasaponins and triterpene glycosides contribute to antiproliferative effects by inducing apoptosis in cancer cell lines such as AGS (gastric), A549 (lung), and HT-29 (colon) without measurable cytotoxicity in normal cell controls.

Scientific Research

Currently, no human clinical trials or meta-analyses have been conducted on Eclipta prostrata. The available evidence is limited to preclinical animal and in vitro studies, such as hair growth promotion in mice and antiproliferative effects on cancer cell lines (PMID: 37959773).

Clinical Summary

The majority of evidence supporting Eclipta prostrata is preclinical, derived from in vitro cell studies and rodent models rather than robust human clinical trials. Antiproliferative activity against AGS, A549, and HT-29 cancer cell lines was demonstrated in a published in vitro study (PMID: 37959773), though human oncology data are absent. Hair growth promotion has been shown in mouse models via mTOR activation, but no large randomized controlled trials in humans have confirmed equivalent efficacy or established effective dosages. Overall, the evidence base is promising but preliminary, and conclusions about clinical benefit in humans cannot yet be drawn with confidence.

Nutritional Profile

Eclipta prostrata (Bhringraj) contains a diverse array of bioactive phytochemicals rather than significant macronutrient content, as it is used medicinally in small quantities rather than as a food source. Key bioactive compounds include: Wedelolactone (0.02–0.1% dry weight), a coumestan compound considered the primary active constituent responsible for hepatoprotective and anti-inflammatory effects; Demethylwedelolactone, a structurally related coumestan present in smaller concentrations alongside wedelolactone. Eclipse albas and ecliptine (alkaloids) are present in trace quantities (~0.08% in aerial parts). Triterpene saponins including eclalbasaponins I–VI are identified in leaf and stem extracts. Polyphenols and flavonoids including luteolin, apigenin, and quercetin derivatives contribute to antioxidant capacity; total phenolic content reported at approximately 18–45 mg GAE/g dry extract depending on solvent and plant part. Phytosterols including beta-sitosterol and stigmasterol are present in the lipid fraction. The plant contains thiophene derivatives (alpha-terthienyl and related compounds) concentrated in roots, with known photosensitizing properties. Coumarin glycosides are present in leaf extracts. Carotenoids including beta-carotene and lutein contribute to the plant's antioxidant profile. Crude protein content of dried aerial parts is approximately 15–18% dry weight; crude fiber approximately 20–25% dry weight; ash content approximately 10–12%. Calcium and iron are the most notable minerals, with iron content reported at approximately 150–200 mg/kg dry weight, relevant to traditional use in anemia. Vitamin C is present in fresh plant material (~30–50 mg/100g fresh weight) but degrades significantly with drying and processing. Bioavailability notes: Wedelolactone has demonstrated moderate oral bioavailability in rodent models; its absorption is enhanced by lipid-based formulations. Traditional oil-based preparations (Bhringraj oil) may improve bioavailability of lipophilic compounds like phytosterols and thiophenes. Aqueous and ethanolic extracts show differing phytochemical profiles, with ethanolic extracts yielding higher wedelolactone concentrations.

Preparation & Dosage

In preclinical studies, mice were administered 1 mg/day (low dose) and 10 mg/day (high dose) of Eclipta extract, with the low dose proving more effective for hair growth. Topical formulations have been used but not specified in dosage. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ashwagandha, Turmeric, Gotu Kola, Brahmi, Neem

Safety & Interactions

Eclipta prostrata is generally considered well-tolerated at traditional Ayurvedic doses, but systematic human safety data are limited. Wedelolactone's NF-κB inhibition may potentiate the effects of anticoagulant medications such as warfarin or NSAIDs, raising bleeding risk, and caution is advised with concurrent use. Due to insufficient safety data, use during pregnancy and lactation is not recommended. Individuals with liver conditions should exercise caution, as high-dose animal studies have noted hepatotoxic potential at supraphysiological concentrations.